Mirabegron: a safety review

Bibliography

• Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(5 Suppl 1):7-12; discussion 12
   PubMed Web of Science ®Google Scholar
• Waine E, Hashim H, Abrams P. Management of the overactive bladder: a review of pharmacological therapies and methods used by the urological specialist. Can J Urol 2007;14(2):3478-88
   PubMedGoogle Scholar
• Chapple CR, Khullar V, Gabriel Z, The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54(3):543-62
   PubMed Web of Science ®Google Scholar
• Staskin DR, MacDiarmid SA. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 2006;119(3 Suppl 1):9-15
   PubMed Web of Science ®Google Scholar
• Olshansky B, Ebinger U, Brum J, Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther 2008;13(4):241-51
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V. Mirabegron, a beta3-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder. IDrugs 2010;13(10):713-22
   PubMed Web of Science ®Google Scholar
• de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol 2006;147(Suppl 2):S25-40
   PubMed Web of Science ®Google Scholar
• Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003;62(5 Suppl 2):28-37; discussion 40-2
   PubMed Web of Science ®Google Scholar
• Tyagi P, Tyagi V, Yoshimura N, Beta3-adrenoceptor agonists for the treatment of overactive bladder. Drugs Fut 2009;34(8):635-40
   Web of Science ®Google Scholar
• Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol 2009;35(1):76-83
   PubMed Web of Science ®Google Scholar
• Chapple CR, Yamaguchi O, Ridder A, Clinical proof of concept study (blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder (Abs 674). European Urology Association Annual Conference; 12 March 2008; Milan, Elsevier BV; 2008. p. 239
   Google Scholar
• Takasu T, Ukai M, Sato S, Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta(3)-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007;321(2):642-7
   PubMed Web of Science ®Google Scholar
• Vij M, Robinson D, Cardozo L. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Emerg Drugs 2010;15(2):299-308
   PubMed Web of Science ®Google Scholar
• van Gelderen EM, Li Q, Meijer J, An exploratory comparison of the single dose pharmacokinetics of the beta 3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 2009;85(Suppl 1):S88
   Google Scholar
• Chapple C, Wyndaele JJ, Van Kerrebroeck P, Dose-Ranging Study Of Once-Daily Mirabegron (Ym178), A novel selective beta3-adrenoceptor agonist, in patients with overactive bladder (OAB) European Urology Association Annual conference; April 2010; Barcelona, Elsevier BV; 2010. p. 249
   Google Scholar
• Krauwinkel WJ, van Gelderen EM, Groen MJ. An open-label, one-sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects (Abs PIII-65). American Society for Clinical Pharmacology and Therapeutics Annual Meeting; 17 – 20 March; Atlanta, 2010. p
   Google Scholar
• Lipworth BJ. Clinical pharmacology of beta 3-adrenoceptors. Br J Clin Pharmacol 1996;42(3):291-300
   PubMed Web of Science ®Google Scholar
• Veltkamp S, van Gelderen M, Schaddelee M, Clinical study into the pharmacokinetic, pharmacodynamic and safety interaction of the novel b3-adrenoceptor agonist mirabegron and metformin in healthy subjects. Basic Clin Pharmacol Toxicol 2009;105(Suppl 1):146
   Google Scholar
• Honda K, Nomiya M, KS. Mutation of beta3-adrenocepor gene: a genetic marker for overactive bladder. Neurourol Urodyn 2006;25:652
   Web of Science ®Google Scholar
• Cisternas MG, Foreman AJ, Marshall TS, Estimating the prevalence and economic burden of overactive bladder among medicare beneficiaries prior to medicare Part D coverage. Curr Med Res Opin 2009;25(4):911-19
   PubMed Web of Science ®Google Scholar
• Hill S, Elhilali M, Millard RJ, Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007;23(11):2697-704
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, Differential Effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50(2):317-26
   PubMed Web of Science ®Google Scholar
• Vrydag W, Michel MC. Agonist induced desensitization of the beta – adrenoceptors in the rat urinary bladder. Naunyn-Schmied Arch Pharmacol 2009;380:257-75
   PubMed Web of Science ®Google Scholar
• Dolan JA, Muenkel HA, Burns MG, Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther 1994;269(3):1000-6
   PubMed Web of Science ®Google Scholar